Tofacitinib as monotherapy in cutaneous polyarteritis nodosa: a case series.

Debaditya RoyVanitha Agrahara SathyanarayanaBhavya NagarajuVijay K R Rao

Published in: Rheumatology advances in practice (2023)

Tofacitinib could be used for disease-free remission as monotherapy for CPAN either upfront or as CS sparing, even without concomitant csDMARDs, in those patients who are dependent on CSs or multiple DMARDs.

Keyphrases

rheumatoid arthritis
end stage renal disease
ulcerative colitis
newly diagnosed
open label
systemic lupus erythematosus
peritoneal dialysis
randomized controlled trial
disease activity
study protocol
patient reported outcomes
patient reported